Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

<h4>Background</h4>We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140...

Full description

Bibliographic Details
Main Authors: Edna O Viegas, Arne Kroidl, Patricia J Munseri, Marco Missanga, Charlotta Nilsson, Nelson Tembe, Asli Bauer, Agricola Joachim, Sarah Joseph, Philipp Mann, Christof Geldmacher, Sue Fleck, Wolfgang Stöhr, Gabriella Scarlatti, Said Aboud, Muhammad Bakari, Leonard Maboko, Michael Hoelscher, Britta Wahren, Merlin L Robb, Jonathan Weber, Sheena McCormack, Gunnel Biberfeld, Ilesh V Jani, Eric Sandström, Eligius Lyamuya, TaMoVac study group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0206838

Internet

https://doi.org/10.1371/journal.pone.0206838

Similar Items